Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts dramatic expansion for the rheumatoid arthritis (RA) drug market. According to a new Pharmacor study, Rheumatoid Arthritis, the launch of new biologic agents, such as Abbott's Humira (adalimumab) and Celltech/Pharmacia/Pfizer's CDP-870, will be major drivers of sales growth.
"As physicians become more comfortable with emerging biologic agent's safety and efficacy profiles, they will extend these agents' use to a growing number of patients," said Bornadata Bain, Ph.D., analyst at Decision Resources. "Initially, these novel agents were prescribed only in patients suffering from the most treatment-refractory disease. However, they are increasingly being used in patients with moderate, rather than severe, RA. We forecast that these agents, whose major-market sales totaled $1.4 billion in 2001, will garner $7.3 billion in 2011."
Disease Background-Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory condition characterized by progressive joint degradation. RA was long viewed as a relatively benign disease, in part because its onset occurs over weeks or months, but it is now established that RA causes substantial destruction to the joints early in its course. According to the American College of Rheumatology, RA costs the U.S. economy nearly $65 billion per year in medical care and indirect expenses such as lost wages and production. The life expectancy for people with RA is 10-15 years less than that of an age-matched person without the disease.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Rheumatoid Arthritis is an Immune & Inflammatory Disorders study.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/